Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with relapsing multiple sclerosis (MS) in high disease activity subgroups with no evidence of disease activity (NEDA) compared with placebo (43.7% vs. 8.7%). The company also shared late-breaking safety analyses including patients with up to eight-years follow-up from monotherapy oral (3.5 mg/kg) cohorts reinforcing safety conclusions of the earlier meta-analysis, as well as an analysis of T lymphocyte (T cells) subpopulations from the ORACLE-MS study demonstrating changes that occur in the adaptive immune system following Cladribine Tablets treatment.Next Story
ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS
Friday, October 27, 2017
You must be logged in to leave a comment.